New Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide

Circulation. 2023 Jul 11;148(2):159-161. doi: 10.1161/CIRCULATIONAHA.123.065407. Epub 2023 Jul 10.

Authors

Ulf Landmesser^{1

2

3

4}, Umidakhon Makhmudova^{1

2}

Affiliations

¹ Department of Cardiology, Angiology, and Intensive Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany (U.L., U.M.).
² Friede Springer Cardiovascular Prevention Center at Charité, Berlin, Germany (U.L., U.M.).
³ DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (U.L.).
⁴ Berlin Institute of Health, Germany (U.L.).

PMID: 37428833
DOI: 10.1161/CIRCULATIONAHA.123.065407

No abstract available

Keywords: Editorials; LDL cholesterol; PCKS9 oral inhibition; PCSK9.

Publication types

Editorial

MeSH terms

Humans
Peptides
Proprotein Convertase 9*
Receptors, LDL* / genetics
Receptors, LDL* / metabolism

Substances

PCSK9 protein, human
Proprotein Convertase 9
Receptors, LDL
Peptides